NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Sun Pharmaceutical Industries Ltd.'s Q1 FY25 operating performance was above our estimate on account of better-than-expected gross margin and lower than expected research and development and and other expenses.
Sun Pharma maintained its R&D expense guidance of 8-10% of sales, for FY25.
India business is expected to grow inline or above the IPM. Effective tax rate is also expected to increase annually.
We marginally upgrade our FY26E EPS estimate by 0.9% and maintain ‘Reduce' rating with revised target price of Rs 1,630 (previously Rs 1,615) at 30 times FY26E P/E.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
